Article

A Novel c-Met/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation.

2023-05-15

Abstract excerpt

It has been reported that c-Met and TRK synergistically promote multiple tumour progression, and therefore blocking the cross-signalling pathway between them may inhibit the growth of multiple tumours. In this study, we developed a tyrosine kinase inhibitor 1D228, which exhibited great anti-tumor activity by targeting TRK and c-Met. In the in vitro models, 1D228 showed a significant better inhibition on cancer cel...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7f2a6d90-a47b-5c86-a0c0-7d926b62302a
DOI: 10.21203/rs.3.rs-2838957/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Novel c-Met/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation.DOI 10.21203/rs.3.rs-2838957/v1Read

Kinase Inhibitors in Multitargeted Cancer TherapySemantic proximity Read

Forty‐nine gastric cancer cell lines with integrative genomic profiling for development of c‐MET inhibitorSemantic proximity Read

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.Semantic proximity Read

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.Semantic proximity Read

EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.Semantic proximity Read

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.Semantic proximity Read

Discovery of Next-Generation Tropomyosin Receptor Kinase (TRK) Inhibitors for Combatting Resistance Associated with Protein MutationSemantic proximity Read

JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.Semantic proximity Read

Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivoSemantic proximity Read

Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivationSemantic proximity Read

Discovery of imidazo[1,2-b]pyridazine derivatives as potent TRK inhibitors for overcoming multiple resistant mutants.Semantic proximity Read

Discovery of novel diarylurea derivatives as potent type II TRK inhibitors for combating multiple acquired resistant mutants.Semantic proximity Read